Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers

• Status: Completed
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial will inform of the role of Low dose ketamine in the acute treatment of severe painful sickle cell crisis in children in a day-case sickle cell centre. The primary aim is to determine whether Low dose ketamine is non inferior to morphine in the management of acute painful sickle cell crises. The specific objectives will be to determine the maximal change in NRS pain score following administration of ketamine and to examine the safety profile of ketamine compared to morphine in this population.

The investigators hypothesize that low dose ketamine will result in similar effective pain control as morphine alone and will not be associated with an increase in adverse events.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Makerere University
• Treatments: Ketamine; Morphine

Criteria

Inclusion Criteria:

• Children aged 7-18 years

• sickle cell anemia patient with severe acute painful crisis

• Parental consent and child assent where applicable

Exclusion Criteria:

• Oxygen saturations below 90% on initial assessment

• Altered conscious and mental state that hinders communication

• Current enrollment in another clinical trial involving an investigational drug.

• History of a stroke

• Hypertension,

• Increased intracranial pressure.

• Glaucoma,

• Failed/ Difficult IV access